Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

NCT05928806 is registered in ClinicalTrials.gov with Michael B. Atkins, MD as lead sponsor.

NCT NCT05928806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05928806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Lead sponsor
Michael B. Atkins, MD
Phase
Phase 2
Overall status
Suspended
Start date
September 25, 2023
Completion date
November 10, 2027
Enrollment
120 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma